Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. We've funded research 30 years ago responsible for identifying the role of the amyloid ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. On Thursday, 6 March, NICE published further draft guidance for public consultation that ...